PetVivo CEO John Lai on Regenerative Therapies, AI Diagnostics, and Equine Health

PetVivo's Mission and Flagship Product

• 🎯 PetVivo's mission is to adapt human therapeutic technologies for the companion animal and equine health sectors.
• 💡 Their primary product, Spryng with OsteoCushion Technology, is an injectable extracellular matrix that mimics cartilage and connective tissue to restore joint function.
• ✅ With over 12,000 animals treated, Spryng has shown significant success in addressing osteoarthritis, lameness, and rehabilitation in dogs and horses.

Precise PRP: A Differentiated Offering

• ⚡ Precise PRP is an allogeneic platelet-rich plasma therapy, meaning it does not require drawing blood from the host animal.
• ⏱️ This approach saves veterinarians over 30 minutes per procedure and ensures a consistent platelet count of approximately 4 billion per vial.
• 🔬 PetVivo's Precise PRP is the only PRP therapy reviewed by the FDA for safety, distinguishing it from competitors.

Innovations in AI and Human Applications

• 🧠 PetVivo is developing a B2B AI platform to assist veterinary doctors with diagnostics, aiming to reduce evaluation time by approximately 80%.
• 📈 The AI platform also helps practice managers optimize customer acquisition costs, potentially reducing them by 80-90%.
• 🤝 Through a partnership with a University of Connecticut spin-off, PetVivo is exploring the use of its treatments for potential human orthopedic applications, aiming to reduce the need for joint replacements.

Vision for Future Animal Health

• 🚀 PetVivo aims to improve veterinary diagnostics and practice efficiency through its AI and product innovations.
• 💰 The ultimate goal is to enhance the quality of pet healthcare and make it more affordable and accessible for owners.